Core Viewpoint - The company has experienced a significant stock price decline, with a cumulative drop of 70% over 30 consecutive trading days, indicating severe abnormal trading fluctuations [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative decline of 70% over the last 30 trading days, which is classified as severe abnormal trading behavior [1] - The company has conducted a self-examination and confirmed that its daily operations are normal, with no major changes occurring [1] Group 2: Business Operations - There have been no significant changes in the market environment or industry policies affecting the company [1] - The internal production and operational order of the company remains normal as of the announcement date [1] Group 3: Corporate Actions - The company has signed a "Termination Agreement" with three other pharmaceutical companies, agreeing to terminate the planned major asset restructuring [1] - The involved parties have reached a consensus to halt the major asset restructuring process [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.66% on October 9, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haichen Pharmaceutical (300584) with a closing price of 63.81, up 13.76% and a trading volume of 155,800 shares, totaling 973 million yuan [1] - Changshan Pharmaceutical (300255) closed at 49.29, up 8.21% with a trading volume of 394,400 shares, totaling 1.916 billion yuan [1] - Conversely, Nanjing New Pharmaceutical (688189) saw a significant drop of 19.96%, closing at 9.10 with a trading volume of 32,300 shares, totaling 29.426 million yuan [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 1.108 billion yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [2] - The capital flow for specific stocks showed: - Changshan Pharmaceutical had a net inflow of 14.6 million yuan from institutional investors, but a net outflow of 14 million yuan from retail investors [3] - Haichen Pharmaceutical recorded a net inflow of 85.3 million yuan from institutional investors, with retail investors showing a net outflow of 68 million yuan [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 南新制药（维权）(688189.SH)20cm跌停，报9.1元，总市值不足25亿元。南新制药公告称，公司近日收到中国证监会出具的《立案告知书》，因公司涉嫌年 报信息披露违法违规，中国证监会决定对公司立案。立案调查期间，公司将积极配合中国证监会的调查工作，并严格按照相关法律法规及监管要求及时履行 信息披露义务。 此外，南新制药筹划的重大资产重组也宣布告终。南新制药此前与西藏未来生物医药股份有限公司、许昌未来制药有限责任公司和合肥市未来药物开发有限 公司签署了《收购意向协议》，公司拟以现金不超过4.8亿元收购未来医药持有的标的资产组。随后，南新制药表示，公司与交易对方就本次交易的可行 性、交易方案的核心条款等进行了多次论证和磋商，但最终未能就本次交易的核心条款达成一致意见，交易各方一致同意终止筹划本次交易。(格隆汇) ...

Core Viewpoint - Nanxin Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of annual report information disclosure, leading to the termination of its cash acquisition of Future Pharmaceutical assets due to failure to reach consensus on key terms [1] Financial Adjustments - The company corrected prior accounting errors, resulting in a reduction of 2023 revenue by 24.5397 million yuan, which is 3.4% of the total annual revenue [1] - The correction significantly impacted the company's net profit, changing from a profit of 3.7515 million yuan to a loss of 10.8687 million yuan for 2023, fundamentally altering the profit-loss status [1] - Due to the retrospective adjustment of accounting errors, the company also revised its financial data for multiple reports in 2024, with the Q1-Q3 2024 revenue adjusted from 226.5709 million yuan to 251.1106 million yuan, an increase of 24.5397 million yuan; the net profit for the same period was adjusted from a loss of 71.8361 million yuan to a loss of 57.2159 million yuan [1]

Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report information disclosure laws, which may lead to civil compensation claims from affected investors [1]. Group 1: Investigation and Legal Actions - The CSRC has decided to initiate an investigation against Nanxin Pharmaceutical due to alleged violations of information disclosure laws as per the Securities Law and Administrative Penalty Law of the People's Republic of China [1]. - Investors who have suffered losses due to the company's alleged fraudulent activities can file civil compensation claims, which may include investment differences, commissions, and stamp duties [1]. - A lawyer from Shanghai Hanlian Law Firm is actively seeking to represent affected investors in compensation lawsuits against Nanxin Pharmaceutical [1]. Group 2: Compensation Conditions - The conditions for compensation claims include investors who purchased Nanxin Pharmaceutical's stocks or bonds before October 1, 2025, and either sold or continued to hold them after this date [1]. - The final conditions for compensation will be adjusted based on the conclusions of the CSRC's administrative penalties and the court's final judgment regarding the legal timeline, compensation targets, and standards [2]. - Investors are advised that while they can initiate lawsuits without the administrative penalty decision, doing so may carry risks of losing the case due to limited investigative means [2]. Group 3: Documentation for Claims - Investors wishing to register for compensation must provide specific documentation, including a copy of their ID, original securities account opening confirmation, and original transaction records from the first purchase to the present [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 上海久诚律师事务所许峰律师团提示，南新制药（维权）（688189）涉嫌虚假陈述引发的投资者索赔案 已经启动。（许峰律师专栏） 2025年10月1日，南新制药（688189）公告近日收到证监会出具的《立案告知书》，因公司涉嫌年报信 息披露违法违规，根据《证券法》《行政处罚法》等法律法规，证监会决定对公司立案。 许峰律师认为，暂定在2025年10月1日之前买入南新制药股票，并且在2025年10月1日后卖出或继续持有 股票的投资者，已可发起索赔。（南新制药维权入口） 除了南新制药投资者索赔案启动，许峰律师代理的腾茂科技（873789）股票操纵索赔案已获得法院立 案，目前正在等待法院的下一步安排，律师团队同步还在继续推进后续案件的立案工作，还在继续接受 其他投资者的索赔委托。 2024年10月28日，证监会对刘洪涛等操纵腾茂科技（873789）股票案作出行政处罚。经查明,刘洪涛、 娄阁存在以下违法事实: 一、刘洪涛、娄阁共同操纵的合作模式 二、刘洪涛、娄阁控制使用证券账户的情况 2023年6月19日至9月28日(以下简称操纵期间),刘洪涛、娄阁实际控制"娄阁"东方财富 ...

消息面上，南新制药发布公告称，公司近日收到中国证监会出具的《立案告知书》。因公司涉嫌年报信 息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证 监会决定对公司立案。 北京商报讯（记者 丁宁）10月9日，南新制药（688189）以跌停开盘，报跌停价9.1元/股，跌幅为 19.96%。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688189 证券简称：南新制药 公告编号：2025-043 湖南南新制药股份有限公司 关于收到中国证券监督管理委员会《立案告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 湖南南新制药股份有限公司（以下简称"公司"）近日收到中国证券监督管理委员会(以下简称"中国证监 会")出具的《立案告知书》（编号：证监立案字0132025024号）。因公司涉嫌年报信息披露违法违规， 根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立 案。 立案调查期间，公司将积极配合中国证监会的调查工作，并严格按照相关法律法规及监管要求及时履行 信息披露义务。 公司指定信息披露媒体为上海证券交易所网站（www.sse.com.cn）和《上海证券报》《中国证券报》 《证券日报》《证券时报》，公司相关信息均以在上述指定媒体刊登的公告为准。敬请广大投资者理性 投资，注意投资风险。 特此公告。 湖南南新制药股份有限公司董事会 2025年10月1日 ...

Key Points - Hainan Huatie's shareholder Hu Danfeng has terminated the share reduction plan and plans to increase holdings in the company with an investment of no less than 30 million yuan and no more than 50 million yuan [2] - Yonghe Co. expects a net profit increase of 447.64% to 506.85% year-on-year for Q3 2025, driven by the high demand in the refrigerant industry and product optimization [3] - Delis Co. is planning a change in company control, leading to a suspension of its stock from October 9, 2025 [4] - BYD reported September 2025 sales of 396,300 new energy vehicles, a slight decrease from 419,400 units in the same month last year, while cumulative sales for the year reached 3.26 million units, up 18.64% [5] - Chipone Technology expects Q3 2025 revenue of 1.284 billion yuan, marking a historical high for the company, with a year-on-year increase of 78.77% [7] - Chipone anticipates a significant improvement in profitability for Q3 2025, with new orders expected to reach 1.593 billion yuan, a year-on-year increase of 145.80% [8] - ST Zhengping's stock will be suspended from trading starting October 9, 2025, due to unusual stock price fluctuations [2][28] - Huanxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [14] - Sichuan Gold won exploration rights for a gold mine in Xinjiang for 510 million yuan, indicating strong geological potential [15]

Group 1 - Nanjing Pharmaceutical (688189.SH) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation due to suspected violations in annual report disclosures [1] - The company will actively cooperate with the CSRC during the investigation and will fulfill its information disclosure obligations in accordance with relevant laws and regulations [1] Group 2 - Nanjing Pharmaceutical has announced the termination of its major asset restructuring plan, which involved a cash acquisition of assets from Future Pharmaceutical [2][3] - The proposed acquisition was valued at no more than 480 million yuan and included both listed and in-development products related to trace element injection solutions [2] - The company had previously signed a letter of intent for the acquisition but failed to reach an agreement on core terms after multiple discussions [3] Group 3 - Nanjing Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share and raised a total of 1.223 billion yuan [3] - The company’s initial public offering (IPO) raised a net amount of 1.135 billion yuan, exceeding the originally planned amount by 466 million yuan [3] - The total issuance costs for the IPO amounted to 87.6177 million yuan, with the lead underwriter, Western Securities, receiving 71.1075 million yuan [3] Group 4 - In 2022, Nanjing Pharmaceutical implemented a capital reserve distribution plan, increasing its total share capital from 140 million shares to 196 million shares by distributing 0.4 shares for every share held [4] - In 2023, the company executed another capital reserve distribution, raising its total share capital to 274.4 million shares with a similar distribution of 0.4 shares for every share held [4]